NARI News & Events

Stryker (SYK) announced that it has completed the acquisition of Inari Medical (NARI), a company that provides innovative solutions for venous thromboembolism, or VTE, clot removal without the use of thrombolytic drugs. The addition of Inari brings an established peripheral vascular position to Stryker in the fast-growing VTE segment. Inari's product portfolio is highly complementary to Stryker's Neurovascular business and includes two novel mechanical thrombectomy solutions-the FlowTriever System for the treatment of pulmonary embolism and the ClotTriever System for thrombectomy in the peripheral vessels-as well as emerging therapies.

Kadant (KAI) will replace Inari Medical (NARI) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 19. S&P 500 constituent Stryker (SYK) is acquiring Inari Medical in a deal expected to be completed soon, pending final closing conditions.

Kadant (KAI) will replace Inari Medical (NARI) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 19. S&P 500 constituent Stryker (SYK) is acquiring Inari Medical in a deal expected to be completed soon, pending final closing conditions.